News | April 28, 2026
Essilor Stellest lens positioned as key breakthrough in myopia control in India
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
Focus on preventive, tech-driven healthcare and digital ecosystem reforms under AB PM-JAY and ABDM
Research by NITI Aayog and All India Institute of Medical Sciences has shown that at least 30% of trauma deaths are linked to delays in emergency response
Exclusive distribution pact with Amcor broadens access to Parafilm M sealing solutions for laboratories, horticulture and industrial users
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Subscribe To Our Newsletter & Stay Updated
